Related Experiment Video
Updated: May 5, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs
1Genitourinary Oncology Service, Sidney Kimmel Center for Prostate & Urologic Cancers, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. slovins@mskcc.org.
Abstract:
Antibodies administered either alone or in a unique construct that can enhance targeting, immunologic recognition and cell killing, remain an area of active interest for a variety of solid tumors. Prostate cancer has unique characteristics as a target for immune-mediated therapies, particularly since it has not only a wide array of antigens expressed on its cell surface, but also has an associated biomarker, which not only can monitor the disease status but also its response to therapy. A number of unique cell surface antigens, as well as internally mediated cell molecules, have shown their clinical activity and efficacy as prostate cancer treatments. The continued evolution of novel antibody-drug and antibody-imaging constructs will probably offer more efficient ways to deliver a therapeutic to the tumor and enhance imaging of active or treated sites of disease.
Insights
Antibody therapies show promise for solid tumors, especially prostate cancer. Novel antibody constructs enhance tumor targeting, immune response, and imaging for better treatment delivery and monitoring.
Area of Science:
- Oncology
- Immunotherapy
- Biotechnology
Background:
- Antibodies are actively investigated for solid tumor treatment, alone or in novel constructs.
- Prostate cancer presents unique therapeutic targets due to its cell surface antigens and biomarkers.
- Existing cell surface antigens and internal molecules show efficacy in prostate cancer treatment.
Purpose of the Study:
- To explore the potential of antibody-based therapies for solid tumors.
- To highlight prostate cancer as a promising target for immunotherapies.
- To discuss the role of novel antibody constructs in improving therapeutic delivery and imaging.
Main Methods:
- Review of current antibody-based therapeutic strategies.
- Analysis of prostate cancer-specific antigens and biomarkers.
- Evaluation of antibody-drug conjugates and antibody-imaging agents.
Main Results:
- Antibodies can enhance tumor targeting, immune recognition, and cell killing.
- Prostate cancer offers multiple antigens and a responsive biomarker for therapy.
- Novel antibody constructs improve therapeutic delivery and disease site imaging.
Conclusions:
- Antibody therapies, particularly novel constructs, hold significant potential for treating solid tumors like prostate cancer.
- Targeting prostate cancer antigens with advanced antibody designs offers improved treatment monitoring and efficacy.
- Continued development of antibody-drug and antibody-imaging constructs will enhance precision medicine in oncology.
